Aclaris Therapeutics, Inc. ACRS

5.15 (0.23) (4.28%) as of 25 Sep
Market cap
$589.0M
P/E
0.0×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
P/S ratio
47.14 10.24 2.35 33.03 122.00 42.46 18.51 37.28 0.00 —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
P/Operating CF
(28.10) (21.45) (10.84) (51.41) (48.31) (31.07) (3.84) (10.51) (38.63) —
P/B ratio
3.58 1.23 0.47 4.97 4.18 7.31 1.12 1.33 3.12 —
EV/Sales
35.78 4.27 (1.41) 25.77 94.02 35.75 1.61 19.31 0.00 —
EV/EBITDA
0.00 0.00 0.46 0.00 0.00 0.00 0.00 0.00 0.00 —
EV/FCF
(5.93) (3.96) 0.55 (11.25) (12.12) (5.93) (0.07) (1.45) (9.12) —
Current Ratio
3.36 3.99 4.16 10.55 8.94 3.87 3.74 6.57 15.69 22.27
Net Debt/EBITDA
1.20 0.80 1.23 2.43 2.13 0.88 0.83 1.67 3.59 2.83
Debt/Equity
0.00 0.00 0.00 0.01 0.01 0.28 0.05 0.14 0.00 0.00
ROE
(50.20%) (84.46%) (49.88%) (44.01%) (77.34%) (94.86%) (113.22%) (60.28%) (34.72%) (36.70%)
ROA
(34.10%) (63.23%) (39.15%) (34.36%) (56.44%) (60.34%) (86.32%) (51.14%) (32.66%) (35.59%)
ROIC
(387.11%) (211.41%) (159.82%) 0.00% (689.92%) 0.00% 0.00% (68.76%) (108.19%) (94.07%)
Return on Tangible Assets
(94.87%) (138.49%) (88.90%) (41.25%) (49.53%) (115.23%) (252.74%) (85.95%) (36.14%) (36.20%)
Average Days of Receivables
259.55 240.94 3.48 5.94 33.63 43.47 60.79 33.41 104.32 —
Earnings Yield
(17.61%) (60.89%) (120.95%) (8.83%) (11.21%) (18.55%) (206.88%) (54.67%) (9.63%) —
Free Cash Flow Yield
(12.80%) (10.54%) (108.64%) (6.94%) (6.36%) (14.20%) (125.30%) (35.67%) (7.95%) —
Free Cash Flow per Share
(0.39) (0.72) (1.14) (1.05) (0.92) (0.92) (2.37) (3.10) (1.99) (1.63)
Book value per Share
0.84 2.01 2.25 3.03 3.48 0.89 1.69 6.54 8.02 7.91
Free Cash Flow
(47.22) (56.01) (79.63) (68.17) (52.44) (39.09) (98.06) (102.17) (55.90) (34.83)
EV/EBIT
0.00 0.00 0.45 0.00 0.00 0.00 0.00 0.00 0.00 —
Other line items

Show all line items

Columns are period end dates